Table 4.
Outcomes of MASLD-HCC from surgical and interventional therapies.
| Treatment | Study Details | Proportion with MASLD | Outcomes | Reference |
|---|---|---|---|---|
| Resection | Meta-analysis of 15 cohort studies/7226 patients | MASLD: 19.5% | MASLD: better DFS and OS | [133] |
| Resection | Meta-analysis of nine studies/5579 patients | MASLD: 20.1% | MASLD: better DFS and OS | [130] |
| Retrospective cohort study via Medicare database: 17,664 patients undergoing curative HCC treatment | MASLD: 33.4% | MASLD improved survival postresection | [128] | |
| OLT | European Liver Transplant Registry analysis 2002–2016/68,950 transplant recipients of all aetiologies (20,195 patients with HCC) | MASLD: 4% MASLD HCC: 5.6% of HCC cohort |
MASLD-HCC vs. ARLD: 10-year post-OLT survival of 46.9% vs. 51.8% slightly worse but no difference compared to HCV (48.2%) | [5] |
| Retrospective cohort design study in two centres in Toronto and San Franciso: OLT for HCCs of all aetiologies in 2004–2014: 929 | MASH: 6.5% | No difference between MASH and non-MASH patients at 1-, 3- and 5-year survival | [134] | |
| Retrospective cohort study via Medicare database: 17,664 patients undergoing curative HCC treatment | MASLD: 33.4% | MASLD: worse median survival than non-MASLD | [128] | |
| RFA | Multi-centre retrospective cohort study of 520 HCC patients of all aetiologies | MASLD: 12.6% | MASLD: no difference in OS, tumour recurrence | [135] |
| Retrospective cohort study via Medicare database: 17,664 patients undergoing curative HCC treatment | MASLD: 33.4% | No significant difference | [128] | |
| All curative therapies | Meta-analysis of nine studies/5579 patients | MASLD: 20.1% | MASLD: better OS and DFS (DFS not statistically significant) | [130] |
| TACE | Single-centre retrospective cohort study of 220 patients treated for 353 HCCs of all aetiologies between 2011 and 2016, U.S. | MASLD: 13.6% | MASLD: no difference in OS, time to progression or complication rates | [136] |
Abbreviations: ARLD, alcohol-related liver disease; DFS, disease free survival; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; MASH, metabolic dysfunction-associated steatohepatitis; MASLD, metabolic dysfunction associated steatotic liver disease; OLT, orthoptic liver transplant; OS, overall survival; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.